Kerman Ronald H
The University of Texas Medical School, Houston, TX 77030, USA.
Heart Fail Clin. 2007 Jan;3(1):1-9. doi: 10.1016/j.hfc.2007.03.003.
New technologies have resulted in the ability to identify the presence of IgG human leukocyte antigen (HLA) or non-HLA antibodies in the sera of potential solid organ transplant recipients. Knowledge of the presence of these antibodies, their antigen specificities, and strength (titer) is crucial to understanding a patient's state of immunologic sensitization and reactivity. Finally, these data, when correlated with sensitive crossmatch results, allow clinicians to make more knowledgeable clinical decisions when paring donors and recipients for transplant.
新技术使人们有能力识别潜在实体器官移植受者血清中是否存在IgG人类白细胞抗原（HLA）或非HLA抗体。了解这些抗体的存在情况、抗原特异性和强度（滴度）对于理解患者的免疫致敏和反应状态至关重要。最后，当这些数据与敏感的交叉配型结果相关联时，临床医生在为移植配对供体和受体时能够做出更明智的临床决策。
